Anticancer CAS 142137-66-1 Osimeertinib Antineoplastic Osimertinib Powder Pharmaceutical Osimertinib

Details :

Osimertinib is active against exon 19 deletions, exon 21 mutations, and also the exon 20 T790M mutations. It is preferentially selective for mutated EGFR, and therefore toxicity at therapeutic doses is lower than for first- and second-generation agents. Notably, osimertinib is able to cross the blood-brain barrier, making it active against disease in the CNS.

Application&Function

AZD9291 used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC). Osimertinib is associated with a moderate rate of serum aminotransferase elevations during therapy and rare instances of clinically apparent acute liver injury.

Anticancer CAS 142137-66-1 Osimeertinib Antineoplastic Osimertinib Powder Pharmaceutical Osimertinib